For the year ending 2025-12-31, LFST had $94,071K increase in cash & cash equivalents over the period. $110,026K in free cash flow.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net income (loss) | 9,663 | -57,443 | -186,262 | -215,564 |
| Depreciation and amortization | 54,753 | 70,950 | 80,437 | 69,198 |
| Non-cash operating lease costs | 41,907 | 39,502 | 39,987 | 38,161 |
| Stock-based compensation | 74,701 | 76,172 | 99,388 | 187,430 |
| Deferred income taxes | 2,422 | -958 | -21,920 | -16,733 |
| Loss on debt extinguishment | 0 | -5,032 | 0 | -3,380 |
| Amortization of discount and debt issue costs | 1,019 | 1,666 | 2,101 | 1,949 |
| Gain on remeasurement of contingent consideration | 0 | 1,725 | 3,972 | -1,688 |
| Loss on disposal of assets | - | - | - | -218 |
| Other, net | -2,030 | -1,431 | -7,080 | - |
| Endowment of shares to lifestance health foundation | - | - | 0 | 0 |
| Patient accounts receivable, net | -36,092 | 6,397 | 24,175 | 21,663 |
| Prepaid expenses and other current assets | 46,685 | 3,332 | 3,070 | 3,431 |
| Accounts payable | -1,563 | 501 | -5,605 | 7,667 |
| Accrued payroll expenses | 25,866 | 14,984 | 26,484 | 12,100 |
| Operating lease liabilities | -48,129 | -46,748 | -37,564 | -13,169 |
| Other accrued expenses | -5,925 | 13,625 | 10,207 | 1,558 |
| Net cash provided by (used in) operating activities | 146,151 | 107,260 | -16,884 | 52,789 |
| Purchases of property and equipment | 36,125 | 21,566 | 40,520 | 79,255 |
| Acquisition of predecessor, net of cash acquired | - | - | - | 0 |
| Acquisitions of businesses, net of cash acquired | 0 | 0 | 19,820 | 60,206 |
| Net cash used in investing activities | -36,125 | -21,566 | -60,340 | -139,461 |
| Proceeds from initial public offering, net of underwriters discounts and commissions and deferred offering costs | - | - | 0 | 0 |
| Contributions from members related to acquisition of predecessor | - | - | - | 0 |
| Issuance of common units to new investors | - | - | 0 | 0 |
| Repurchase of series a redeemable convertible preferred units | - | - | - | 0 |
| Proceeds from long-term debt, net of discount | 0 | 287,809 | 57,753 | 257,324 |
| Payments of debt issue costs | 0 | 1,818 | 188 | 7,266 |
| Payments of long-term debt | 7,250 | 289,494 | 2,470 | 187,766 |
| Prepayment for debt paydown | - | 0 | 0 | 1,609 |
| Payments of contingent consideration | 0 | 6,444 | 7,668 | 12,515 |
| Taxes related to net share settlement of equity awards | 8,705 | 0 | 0 | 904 |
| Net cash (used in) provided by financing activities | -15,955 | -9,947 | 47,427 | 47,264 |
| Net increase (decrease) in cash and cash equivalents | 94,071 | 75,747 | -29,797 | -39,408 |
| Cash and cash equivalents - beginning of period | 154,571 | 78,824 | 108,621 | 148,029 |
| Cash and cash equivalents end of period | 248,642 | 154,571 | 78,824 | 108,621 |
LifeStance Health Group, Inc. (LFST)
LifeStance Health Group, Inc. (LFST)